VC Enthusiasm For Gene Therapy Is Going Viral
Executive Summary
Audentes is the latest gene therapy start-up to land a large Series A round, taking $30 million to explore treatments for two rare muscle diseases. It’s another sign that VCs believe the risks around gene therapy are continuing to abate – and that pharmas aren’t far behind them.